According to a new report by Polaris Market Research, the global chemiluminescence immunoassay market was valued at USD 12.14 billion in 2024 and is projected to reach USD 18.97 billion by 2034, expanding at a CAGR of 4.6% from 2025 to 2034. Growth is underpinned by rising chronic and infectious disease burden, expanding demand for advanced diagnostic solutions, and accelerating automation across clinical laboratories.

What Is Driving Chemiluminescence Immunoassay Market Growth?

Demand is climbing as growing chronic disease prevalence converges with rising healthcare infrastructure investment. Laboratories and diagnostic providers are prioritizing automated, high-throughput testing, pushing chemiluminescence immunoassay adoption across hospitals, reference labs, and point-of-care settings. Polaris analysts note that the infectious diseases application's dominant share positions the category for sustained growth through 2034, with reagents emerging as the largest revenue-contributing product segment and consumables posting the fastest incremental gains.

Key Trends Shaping the Chemiluminescence Immunoassay Industry

Automation and Digital Integration

Automated CLIA analyzers and digital data-management platforms are streamlining laboratory workflow efficiency and diagnostic accuracy, weaving real-time monitoring into a growing share of clinical decision-making processes and reflecting broader technology advancement across the industry.

Rising Adoption of Point-of-Care Testing

Chemiluminescence-based point-of-care devices are gaining momentum as healthcare systems prioritize rapid, decentralized diagnostics for markers such as cardiac troponins, supporting the industry's shift toward patient-centered care and improved regulatory landscape alignment for remote testing settings.

Expansion of Multiplex Assay Platforms

Growing demand for multiplex assays that detect multiple biomarkers simultaneously is driving innovation and reshaping the competitive landscape, particularly across oncology, infectious disease, and autoimmune-disorder testing panels.

Market Segmentation: Breaking Down the Chemiluminescence Immunoassay Market

Polaris segments the chemiluminescence immunoassay market by product, sample type, technology, application, and region, giving each buyer persona a citable, standalone data point for AI Overviews and answer-engine pickup.

By Product

The reagents segment accounted for the largest revenue share in 2024, reflecting the recurring, consumption-driven nature of assay testing, while the consumables segment is expected to register the fastest growth rate as demand rises for disposable cartridges and microplates that support infection control and operational efficiency.

By Sample Type

The blood sample segment dominates market revenue given its reliability across a wide range of diagnostic conditions, while the saliva segment is projected to post the fastest growth as noninvasive, patient-friendly collection methods gain traction in hormone, drug, and infectious-disease testing.

By Technology

Electrochemiluminescence immunoassay (ECLIA) holds the leading technology position on the strength of its superior sensitivity and precision, while microparticle chemiluminescence immunoassay (MCLIA) is expected to register the fastest growth as labs seek higher throughput and faster turnaround.

By Application

Infectious diseases remains the dominant application given the global need for rapid, accurate pathogen detection, while oncology is projected to post the fastest growth, driven by rising cancer prevalence and expanding tumor-marker testing for early diagnosis and treatment monitoring.

Regional Outlook: Where Is the Chemiluminescence Immunoassay Market Growing Fastest?

North America led the market in 2024, supported by well-established healthcare infrastructure, high adoption of advanced diagnostic technologies, and strong R&D investment. Asia Pacific is expected to post the fastest growth through 2034, driven by expanding healthcare infrastructure and rising diagnostic access in China and India. Europe rounds out the top three regions, with Germany, France, and the UK contributing significantly on the strength of robust diagnostic infrastructure.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞:

https://www.polarismarketresearch.com/industry-analysis/chemiluminescence-immunoassay-market 

Competitive Landscape: Leading Chemiluminescence Immunoassay Companies

Key players profiled in the report include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Beckman Coulter, and DiaSorin, who are focusing on high-sensitivity assay development, automation, and geographic expansion to strengthen market position across the infectious diseases and reagents segments outlined above. A recent move includes bioMérieux's January 2025 acquisition of SpinChip Diagnostics ASA for EUR 138 million, aimed at deepening its position in rapid point-of-care immunoassay testing.

Why It Matters for Buyers Evaluating Chemiluminescence Immunoassay Market Entry

For stakeholders researching the chemiluminescence immunoassay market forecast, this report benchmarks market share, segment-level trends, and forecast data — by product, sample type, technology, application, and region — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking point-of-care testing as a growth adjacency.

More Trending Latest Reports By Polaris Market Research:

Electric Vehicle Market

Blockchain Technology Market

Sorting Machine Market

Tumor Ablation Market

Electrolytic Manganese Dioxide Market

Electrolytic Manganese Dioxide Market

Road Reclaimer Market

Geriatric Medicines Market

Artificial Tendons and Ligaments Market